BOT - Anything but charting, page-8380

One of the big components of BOT's value proposition is time to market and marketing strategy. I think some of the key factors that separate BOT from other biotech's with a pending FDA approval are:


Distribution:

Post approval, and if I recall correctly, Eversana (3PL provider) is available to distribute very soon after approval. "Using a 3PL cuts down time to market from a year to a few weeks and does not require capital spend."

Accessibility:

Using telehealth, patients can effectively qualify same day for a prescription "hours for a prescription" and have Sofdra in the same week, with the option to have auto-refills; all from just using their smartphone and without leaving the house.



Marketing:

Based on the demographic that would be most likely to use telemedicine, by targeting TikTok, Instagram, YouTube and other social media I believe BOT will have huge exposure for little cost. I know that I have been shown ads for Carpe anti-sweat deodorant on Facebook, Google feed and even Instagram influencers on 'reels'. This is without me ever searching for anti sweat drugs, only researching BOT although I am sure the websites I am visiting are being fed into the algorithms to show me these ads. Now, imagine someone actively searching for anti sweat applications or alternatives to Botox, Qbrexza etc.

The launch strategy, combined with boots on ground will hopefully result in sales being generated potentially within the first month post-launch. I'm looking forward to see the sign-up page for patients post June 20, hopefully sooner!